Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-csbD bovine immunoglobulin G
- Development stage
- Phase 2
- Lead developer
- Johns Hopkins Bloomberg School of Public Health
- Modality
- Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
Anti-CsbD bovine immunoglobulin G is a hyperimmune bovine milk immunoglobulin product specifically targeting CsbD, which is a minor fimbrial adhesin component of CS17 fimbriae found in enterotoxigenic Escherichia coli (ETEC). It is designed to provide passive immunity against ETEC-induced diarrhea when administered orally. The product works by binding to the CsbD adhesin, potentially preventing bacterial attachment to intestinal cells and inhibiting colonization.
- Other names
- Anti-CsbD Bovine IgGAnti-CsbD bovine milk IgG
02
Targets
CS17 (Coli surface antigen 17)
Beyond the preview
Go deeper on anti-csbD bovine immunoglobulin G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-csbD bovine immunoglobulin G.